235 related articles for article (PubMed ID: 16188170)
1. Drugs on the horizon for diabesity.
Bailey CJ
Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170
[TBL] [Abstract][Full Text] [Related]
2. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Kendall DM; Kim D; Maggs D
Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
[TBL] [Abstract][Full Text] [Related]
3. New drugs for type 2 diabetes mellitus: what is their place in therapy?
Krentz AJ; Patel MB; Bailey CJ
Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
10. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
Mentlein R
Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
14. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
Nicholls SJ; Uno K
Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
[TBL] [Abstract][Full Text] [Related]
16. Diabetes: assessing the pipeline.
Lebovitz H
Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
[TBL] [Abstract][Full Text] [Related]
17. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
Savkur RS; Miller AR
Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.
Lebovitz HE
Endocr Pract; 2006; 12 Suppl 1():142-7. PubMed ID: 16627399
[TBL] [Abstract][Full Text] [Related]
20. [New oral antidiabetic agents--clinical perspectives].
Fischer S; Bornstein SR
Internist (Berl); 2008 Apr; 49(4):495-501. PubMed ID: 18330534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
